Feasibility study of local therapy including surgical resection in patients with clinical stageIV non-small cell lung cancer (NSCLC) who receive induction systemic therapy

Feasibility study of local therapy including surgical resection in patients with clinical stageIV non-small cell lung cancer (NSCLC) who receive induction systemic therapy - Feasibility study of local therapy including surgical resection in patients with clinical stageIV non-small cell lung cancer (NSCLC) who receive induction systemic therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025503

Enrollment

Registered

2017-01-04

Start date

2017-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Operation Radiation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically or cytological proven clinical stage4 nonsmall cell carcinoma who receive induction systemic therapy. 2) Systemic therapy more than 12 months 3) Cases has a possibility of the radical cure resectability by lobectomy about the primary lesion at the maximum 4) Cases has a possibility of the radical therapy (surgery or radiation) about the metastatic lesion. 5) Adequate organ function. 6) Expected FEV 1.0 > 800ml after lung resection, SpO2 (Room air) >90% or PaO2 >= 65 torr. 7) Age >=20, <=75 y 8) ECOG PS 0-1 9) Cases indicating following organ (bone marrow, liver, kidney and lung) functions 10) Patients providing the written informed consent.

Exclusion criteria

Exclusion criteria: 1) History of dissemination or malignant effusion. 2) Brain Metastasis with the severe symptom 3) Uncontrollable systemic disease (hyper tension, diabetes mellitus etc.) 4) History of active double cancer 5) History of active infection 6) Interstitial pneumonia or pulmonary fibrosis detectable on chest Xp 7) History of continuous steroidal treatment or Immunosuppressive drug. 8) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator

Design outcomes

Primary

Measure	Time frame
1-year progression-free survival	—

Secondary

Measure	Time frame
2-year progression-free survival Overall Survival Safety Post operative Quality of life	—

Countries

Japan

Contacts

Public ContactHirofumi Uehara

Teikyo University school of Medicine Surgery

hirofumi.uehara@med.teikyo-u.ac.jp03-3964-1231

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026